Dow Jones

40 211,72

0,00%

DAX

Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NASDAQ
Summit Therapeutics Inc (SMMT)
Summit Therapeutics Inc (SMMT) Actualités

SMMT

Summit Therapeutics (SMMT)

Summit Therapeutics Inc

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:SMMT

<< Précédent 1 2 3 4 5 6 7 8 9 10 11 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
15/06/2017	13h00	GlobeNewswire Inc.	Summit Therapeutics to Participate in JMP Securities Life Sciences Conference	NASDAQ:SMMT	Summit Therapeutics Inc
14/06/2017	22h16	Edgar (US Regulatory)	Report of Foreign Issuer (6-k)	NASDAQ:SMMT	Summit Therapeutics Inc
14/06/2017	13h00	GlobeNewswire Inc.	Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2017 and Operational Progress	NASDAQ:SMMT	Summit Therapeutics Inc
13/06/2017	13h00	GlobeNewswire Inc.	Summit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2017 on 14 June 2017	NASDAQ:SMMT	Summit Therapeutics Inc
05/06/2017	13h00	GlobeNewswire Inc.	Summit Presents Positive New Preclinical Data on Novel CDI Antibiotic Ridinilazole at ASM Microbe 2017	NASDAQ:SMMT	Summit Therapeutics Inc
23/05/2017	13h00	GlobeNewswire Inc.	Summit Announces Key Appointments to Strengthen Research and Development Team	NASDAQ:SMMT	Summit Therapeutics Inc
15/05/2017	13h00	GlobeNewswire Inc.	Summit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMD	NASDAQ:SMMT	Summit Therapeutics Inc
29/04/2017	00h30	GlobeNewswire Inc.	Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summit’s Ridinilazole Achieved Stati...	NASDAQ:SMMT	Summit Therapeutics Inc
27/04/2017	17h25	Edgar (US Regulatory)	Confidential Treatment Order (ct Order)	NASDAQ:SMMT	Summit Therapeutics Inc
30/03/2017	13h00	GlobeNewswire Inc.	Summit Therapeutics to Present at the Needham Healthcare Conference	NASDAQ:SMMT	Summit Therapeutics Inc
29/03/2017	13h00	GlobeNewswire Inc.	Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational Pr...	NASDAQ:SMMT	Summit Therapeutics Inc
27/03/2017	13h00	GlobeNewswire Inc.	Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017	NASDAQ:SMMT	Summit Therapeutics Inc
27/03/2017	13h00	GlobeNewswire Inc.	Summit to Extend Ongoing PhaseOut DMD Clinical Trial of Ezutromid in Patients With DMD	NASDAQ:SMMT	Summit Therapeutics Inc
15/03/2017	12h00	GlobeNewswire Inc.	Summit Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference	NASDAQ:SMMT	Summit Therapeutics Inc
28/02/2017	13h00	GlobeNewswire Inc.	Summit Therapeutics Recognises 10th Annual Rare Disease Day	NASDAQ:SMMT	Summit Therapeutics Inc
14/02/2017	21h01	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:SMMT	Summit Therapeutics Inc
02/02/2017	13h00	GlobeNewswire Inc.	Summit Therapeutics to Participate in February Investor Conferences	NASDAQ:SMMT	Summit Therapeutics Inc
01/02/2017	13h00	GlobeNewswire Inc.	Summit Outlines Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Following FDA and EMA Regulatory Meetings	NASDAQ:SMMT	Summit Therapeutics Inc
18/01/2017	13h00	GlobeNewswire Inc.	Summit Appoints Dr David Roblin as Chief Operating Officer and President of Research & Development	NASDAQ:SMMT	Summit Therapeutics Inc
15/12/2016	13h00	GlobeNewswire Inc.	Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2016 and Operational Progress	NASDAQ:SMMT	Summit Therapeutics Inc
13/12/2016	16h00	GlobeNewswire Inc.	Summit Therapeutics to Report Financial Results for the Third Quarter Ended 31 October 2016 on 15 December 2016	NASDAQ:SMMT	Summit Therapeutics Inc
16/11/2016	13h00	GlobeNewswire Inc.	Summit Enrols Patients in the United States Into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients With DMD	NASDAQ:SMMT	Summit Therapeutics Inc
06/10/2016	13h00	GlobeNewswire Inc.	Summit Therapeutics Presents Preclinical DMD Data at the 21st International Congress of the World Muscle Society	NASDAQ:SMMT	Summit Therapeutics Inc
04/10/2016	13h01	GlobeNewswire Inc.	Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for Europea...	NASDAQ:SMMT	Summit Therapeutics Inc
04/10/2016	13h00	GlobeNewswire Inc.	Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Ut...	NASDAQ:SMMT	Summit Therapeutics Inc
27/09/2016	13h00	GlobeNewswire Inc.	Summit Receives Rare Pediatric Disease Designation From US FDA for Ezutromid in Treatment of Duchenne Muscular Dystrophy	NASDAQ:SMMT	Summit Therapeutics Inc
26/09/2016	13h00	GlobeNewswire Inc.	Summit Receives Fast Track Designation From US FDA for Ezutromid in the Treatment of Duchenne Muscular Dystrophy	NASDAQ:SMMT	Summit Therapeutics Inc
12/09/2016	13h00	GlobeNewswire Inc.	Summit Launches Online Resource on Utrophin Modulation for the Duchenne Muscular Dystrophy Community	NASDAQ:SMMT	Summit Therapeutics Inc
08/09/2016	13h00	GlobeNewswire Inc.	Summit Therapeutics Reports Financial Results for the Second Quarter Ended 31 July 2016 and Operational Progress	NASDAQ:SMMT	Summit Therapeutics Inc
07/09/2016	13h00	GlobeNewswire Inc.	Summit Therapeutics to Present at 18th Annual Rodman & Renshaw Global Investment Conference	NASDAQ:SMMT	Summit Therapeutics Inc